前两年的流行季，曾出现过一些进口抗流感特效药短缺、价格上涨的情况，值得关注的是，今年以来，多款国产抗流感创新药获批上市，有评论甚至认 为，2025年是"国产流感创新药元年"。这些药品的出现，能缓解流感流行季公众对于药品的更多需求吗？国产创新药如何更好地破局？ 晚上9点多，北京一家连锁大药房内，一位妈妈正在给8岁的孩子挑选抗流感特效药。 货架上，两款进口抗流感特效药旁，还有多款国产药。 某网上购药平台工作人员向中国之声介绍，11月以来甲乙流特效药订单量增长超1倍。东北、华北及南方部分城市需求增幅显著。具体城市表现来看， 哈尔滨、沈阳、呼和浩特、太原、西安等北方城市订单量增幅超150%；南方城市里，成都、重庆需求较为突出，订单量增幅超1倍。山西某医药公司工作人 员康涛接受采访时介绍，从公司采购数据表现来看，10 月中旬开始，感冒、退热药的采购量是其他月份的两至三倍。他说："一定会保证大家用药，老百姓 肯定能买到。" 北京一家连锁大药房内，一位妈妈正在给8岁的孩子挑选抗流感特效药（记者周益帆 摄） 央广网北京11月19日消息（总台中国之声记者周益帆）据中央广播电视总台中国之声报道，伴随着秋冬换季降温，全国整体进入流 ...

11月以来，全国整体进入流感流行季。 据央视新闻消息，在国家疾控局11月10日举行的新闻发布会上，中国疾病预防控制中心病毒病所研究员 王大燕介绍，预计今年秋冬季我国流感疫情高峰可能出现在12月中下旬和1月初。 电商平台中，部分流感药已悄悄降价，意图抢占市场。11月13日，新京报贝壳财经记者在京东大药房看 到，20mg2片规格的伊速达显示原价320元，自11月3日零点起，到手价为196元。 同类竞品中，2024年流感季曾爆火的速福达，40mg1片装售价210元/盒。0.2g15片的安睿威标价则为179 元/盒；40mg2片规格的济可舒，标价为320元/盒。 凭借"单剂量给药"的便捷性，此前，速福达一度成为市场新宠，搅动传统流感药市场格局。不过，2025 年，多款国产流感创新药密集上市，曾经一盒难求的"流感神药"正被包围。 曾抢手的"流感神药"，药店供应充足 "去年来问的人特别多，一到货就卖得特别快，今年也有很多人咨询，目前还都有货。"11月17日，当问 及速福达的供应情况，北京市通州区一家药店的店员对新京报贝壳财经记者表示。 当天，新京报贝壳财经记者走访多家药店了解到，速福达目前供应充足，线下药店售价在239元 ...

Core Viewpoint - The flu season in China is expected to peak in mid to late December and early January, leading to increased competition among flu medication manufacturers as prices drop to capture market share [5][8]. Group 1: Market Dynamics - Some flu medications have seen price reductions on e-commerce platforms, with the price of 20mg of Isodax dropping from 320 yuan to 196 yuan since November 3 [6]. - The market for flu medications is becoming increasingly competitive, with several new domestic flu drugs set to launch in 2025, challenging the previously dominant "miracle drug" status of Sufuda [8][23]. - Sufuda, a product of Roche, was initially priced at 498 yuan per box before being included in the national medical insurance directory, which reduced its price to 222.36 yuan [14]. Group 2: Supply and Demand - Sufuda is currently in ample supply, with prices in physical pharmacies ranging from 239 yuan to 258 yuan per box, and no immediate price adjustments are anticipated [10]. - The demand for Sufuda remains high, with reports indicating that it sells out quickly during peak seasons [9]. Group 3: Competitive Landscape - Oseltamivir, a traditional flu antiviral, holds over 80% market share in China's flu medication market, with prices significantly reduced due to increased competition and centralized procurement [16][19]. - The lowest bid price for Oseltamivir capsules has dropped to less than 1 yuan per capsule, marking an 85% decrease from previous prices [21]. - New domestic flu drugs, such as Isodax and Anruwei, are entering the market, aiming to capture a share of the growing demand for flu treatments [24][30]. Group 4: Regulatory Developments - The National Medical Products Administration has accepted new drug applications for several flu medications, indicating a proactive approach by domestic companies to expand their product offerings [28]. - Companies are also working to include their products in the medical insurance directory to enhance accessibility for patients [30][31].

Core Viewpoint - The article discusses the anticipated flu season in China, highlighting the expected peak in December and January, along with the current trends in flu virus strains and the availability of antiviral medications [3][4]. Group 1: Flu Season Forecast - The peak of the flu season in China is expected to occur in mid to late December and early January [3]. - Shanghai has reported a rising positive detection rate for flu, indicating the onset of the flu epidemic season [3]. Group 2: Virus Strain Variations - The dominant flu strain in Shanghai has shifted from H1N1 in the first half of the year to H3N2 in the latter half [3]. - Current strains remain highly sensitive to existing antiviral medications, including neuraminidase inhibitors and polymerase inhibitors [3]. Group 3: Antiviral Drug Availability - Hospitals in Shanghai have sufficient supplies of medications to combat respiratory infections, including azithromycin for mycoplasma infections [3]. - The price of the antiviral drug Marbalozav (Sufuda) remains stable at approximately 200 yuan for a 40mg tablet, with children's formulations priced around 250 yuan [4]. Group 4: New Domestic Antiviral Drugs - Two new domestic antiviral drugs, Masurazav (Yisuda) and Masilozav (Jikeshou), have been approved, both requiring only a single dose for treatment [4]. - The prices for these new drugs are lower than Marbalozav, with Jikeshou priced at about 160 yuan for a 40mg tablet and Yisuda at 200 yuan for two 20mg tablets [4]. Group 5: Resistance Issues - Clinical studies indicate low resistance rates for the new antiviral drugs, with mutation rates for H1N1 and H3N2 strains at 0.7% and 0.9% respectively, suggesting a low risk of resistance [4].

Core Viewpoint - JD Health reported strong financial performance for the first half of 2025, with significant growth in revenue and profit driven by the sales of pharmaceutical and health products [1] Financial Performance - The company achieved revenue of 35.29 billion yuan, representing a year-on-year growth of 24.5% [1] - Operating profit reached 2.13 billion yuan, marking a substantial increase of 105.5% year-on-year [1] - Net profit attributable to shareholders was 2.60 billion yuan, reflecting a year-on-year growth of 27.45% [1] Business Segments - JD Health's revenue growth was primarily fueled by the sales of pharmaceutical and health products, which increased by 22.7% to 29.3 billion yuan compared to the same period last year [1] - The company launched over 30 innovative drugs online in the first half of the year, including weight loss drug Xin'ermei and hypertension treatment drug Xinchao Tuo [1] User Engagement and Platform Growth - As of June 30, 2025, the number of merchants on JD Health's platform exceeded 150,000, an increase of over 50,000 since December 31, 2024 [1] - The annual active user count surpassed 200 million, with an average of over 500,000 consultations per day in the first half of the year [1]

Core Insights - JD Health reported a total revenue of RMB 35.3 billion for the first half of 2025, representing a year-on-year growth of 24.5%, with a Non-IFRS net profit of RMB 3.57 billion, up 35% [1] - The company has surpassed 200 million annual active users and has over 150,000 third-party merchants on its platform [1] - JD Health is enhancing its supply chain capabilities and solidifying its position as the leading online health consumption platform [1][3] Financial Performance - Total revenue for the first half of 2025 reached RMB 35.3 billion, a 24.5% increase compared to the previous year [1] - Non-IFRS net profit was RMB 3.57 billion, reflecting a 35% year-on-year growth [1] User Engagement and Market Position - As of June 30, 2025, JD Health has over 200 million annual active users and more than 150,000 third-party merchants [1][3] - The average daily consultation volume at JD Internet Hospital exceeded 500,000 [5][6] Supply Chain and Product Offerings - JD Health is strengthening its omni-channel supply chain capabilities, collaborating with leading pharmaceutical companies to expand product offerings [3] - The company launched over 30 innovative drugs online, reinforcing its position as the first stop for new specialty drugs [3][4] Service Integration and Healthcare Model - JD Health is enhancing its "medical, testing, diagnosis, and medication" service loop, focusing on personalized health needs [5][6] - The company has developed a five-specialty system in areas such as dermatology and mental health, providing tailored treatment plans [6] Technological Innovation - JD Health is leveraging AI technology to enhance healthcare services, with over 50 million users served by its AI products [7] - The company has introduced AI-driven solutions for both patients and healthcare professionals, improving service efficiency [7] Social Responsibility and Market Trends - JD Health is actively involved in social responsibility initiatives, supporting rare disease patients and disaster relief efforts [8] - The company is positioned to capitalize on the growing health consumption market as public health awareness increases [8] Future Outlook - JD Health aims to deepen its omni-channel layout and enhance the accessibility of health products and services [9] - The company plans to expand its professional resources and further integrate AI applications in healthcare services [9]